Cogent Biosciences, Inc.
COGT
Hisse Senetlerindeki Sıralama
#3333
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Hisse Fiyatı
$30.65
Piyasa Değeri
$5.32B
Değişim (1 gün)
2.13%
Değişim (1 yıl)
88.96%
Ülke
US
Ticaret Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Cogent Biosciences, Inc. (COGT) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-377.18M
Cogent Biosciences, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-377.18M'dir. 2023 yılında şirket $-192.41M kazanç elde etti, bu 2022 yılındaki $-140.24M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Cogent Biosciences, Inc. için kazanç geçmişi 2015 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-377.18M | 47.42% |
| 2024 | $-255.86M | 32.98% |
| 2023 | $-192.41M | 37.20% |
| 2022 | $-140.24M | 94.04% |
| 2021 | $-72.27M | -3.39% |
| 2020 | $-74.81M | 135.00% |
| 2019 | $-31.83M | -7.82% |
| 2018 | $-34.53M | 35.46% |
| 2017 | $-25.49M | 40.65% |
| 2016 | $-18.12M | 174.94% |
| 2015 | $-6.59M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,498.51% |
US
|
|
| $-3.09B | 718.44% |
US
|
|
| $-4.02B | 964.80% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -617.17% |
NL
|
